Announcement PDF Market Announcement 26 March 2026 26 March 2026 Market Announcement 1/1 ASX Limited ASX Customer Service Centre 131 279 | asx.com.au #11063508v1 Atomo Diagnostics Limited (ASX: AT1) – Trading Halt Trading in the securities of Atomo Diagnostics Limited (‘AT1’) will be halted at the request of AT1, pending the release of an announcement by AT1. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of: • the commencement of normal trading on Monday, 30 March 2026; or • the release of the announcement to the market. AT1’s request for a trading halt is attached below for the information of the market. Issued by ASX Compliance Atomo Diagnostics Limited ACN 142 925 684 Level 1, 3-5 George St Leichhardt NSW 2040 26 March 2026 ASX Compliance Pty Limited 39 Martin Place Sydney NSW 2000 Delivered via email: TradingHaltsSydney@asx.com.au Dear ASX Compliance, REQUEST FOR TRADING HALT Atomo Diagnostics Limited (ASX: AT1) (the Company) requests an immediate halt to the trading of the Company’s securities (ASX: AT1) quoted on the Australian Securities Exchange (ASX) in accordance with ASX Listing Rule 17.1. The trading halt is requested to enable the Company to update the market on the FDA response to the FebriDx® CLIA waiver application submitted by Lumos Diagnostics Holdings Ltd (ASX: LDX). As previously disclosed to the market, the Company is the exclusive licensor, manufacturer and supplier of Pascal cassettes to LDX for FebriDx® of which the FDA decision will materially impact the volume of sales of the FebriDx® test, each of which requires the Company’s Pascal cassette (stated purpose). In accordance with ASX Listing Rule 17.1, the Company provides the following information in relation to the request: 1. The trading halt is necessary to assist the Company in managing its continuous disclosure obligations as the Company expects to make an announcement to the market in relation to the stated purpose above. 2. The Company requests that the trading halt remains in place until the earlier of commencement of normal trading on Monday, 30 March 2026, or when the Company’s announcement regarding the stated purpose is released to the market. 3. The Company expects to make the announcement to the market before the commencement of normal trading on Monday, 30 March 2026. 4. The Company is not aware of any reason why the trading halt should not be granted or of any further information necessary to inform the market about the trading halt. Please contact me if you require any further information concerning this matter. Yours sincerely, Mathew Watkins Company Secretary